Kenneth Ouriel, MD, MBA, Co-Chairman, VEITHsymposium and President & CEO, Syntactx notes, "Medical device, pharmaceutical and diagnostics companies will present their newest, most interesting and most innovative products to the investment community at the
New York, NY (PRWEB) November 17, 2014
Kenneth Ouriel, MD, MBA, Co-Chairman, VEITHsymposium and President & CEO, Syntactx notes, "Medical device, pharmaceutical and diagnostics companies will present their newest, most interesting and most innovative products to the investment community at the 41st Annual VEITHsymposium in New York, Friday, November 21, 2014, 1-4 P.M. in the Gramercy Suite West, 2nd Floor, New York Hilton-Midtown, 1335 Avenue of the Americas, NY, NY. Media is invited to attend.
For over 40 years, VEITHsymposium has been the global medical education leader providing vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features over 900 rapid-fire presentations from world-renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Global industry medical device companies will be exhibiting. During the innovation and investment roundtable session, presenters will include senior/executive leaders from the below noted companies, each with products in the cardiovascular arena. What better venue than a premier international vascular continuing medical education meeting to meet industry executives and learn more about their future technologies and investment opportunities. For this special roundtable session, the audience will include individuals from the financial services industry – venture capitalists, private equity investors, investment management people and others.
INNOVATION + INVESTMENT
Moderator: Kenneth Ouriel, MD, MBA
Co-Chairman, VEITHsymposium and
President & CEO, Syntactx
A g e n d a
1:00 – 1:10 I&I Roundtable: Introducing a New Addition to the VEITHsymposium, Kenneth Ouriel, VEITHsymposium Co-Chairman
1:10 – 1:20 Nellix: Transforming AAA Therapy, Presentation by Bob Mitchell, President, Endologix
1:21 – 1:29 Discussion of Endologix Presentation
1:30 – 1:40 Why Venous? Presentation by Scott Solano, CEO Veniti
1:41 – 1:49 Discussion of Veniti Presentation
1:50 – 2:00 Successful Dissection Repair: Minimize Metal, Minimize Force, Maximize Healing, Presentation by Bruce J. Shook, CEO Intact Vascular
2:01 – 2:09 Discussion of Intact Vascular Presentation
2:10 – 2:20 SPNC-Specialty Solutions for Challenging Cardiovascular Indications, Presentation by Shar Matin, COO Spectranetics
2:21 – 2:29 Discussion of Spectranetics Presentation
2:30 – 2:40 Personalized Drug Choice and Dosing: Time to Look at Genetics, Presentation by Michael Stewart, CEO Companion Dx
2:41 – 2:49 Discussion of Companion Dx Presentation
2:50 – 3:00 BTG Interventional Vascular Technology, Presentation by Matt Stupfel, Vice President and General Manager, EKOS Corporation (BTG)
3:01 – 3:09 Discussion of EKOS/BTG Presentation
3:10 – 3:20 Commercializing Our Scientific Results, Presentation by James Reinstein, CEO Aptus Endosystems
3:21 – 3:29 Discussion of Aptus Presentation
3:30 – 3:40 Kissing and Mating – An AAA Love Affair, Presentation by G. Ray Martin, President and CEO Altura Medical
3:41 – 3:49 Discussion of Altura Medical Presentation
3:50 – 4:00 Multilayer Flow Modulator: A Paradigm Shift for Aneurysm Treatment, Presentation by Noureddine Frid, CEO Cardiatis
4:01 – 4:09 Discussion of Cardiatis Presentation
4:10 – 4:15 Closing Comments by Kenneth Ouriel, VEITHsymposium Co-Chairman